
Supplementary information

Rapid detection of SARS-CoV-2 RNA in saliva via Cas13

In the format provided by the authors and unedited

1	Contents
2	Supplementary Table 1: LAMP primer sets screened, Related to Figure 2
3	Supplementary Table 2: LAMP, rLAMP, qRT-PCR, and Cas13 sequences
4	Supplementary Table 3: Fluidics calibration volumes
5	Supplementary Table 4. Cost breakdown
6	Supplementary Table 5. Clinical Saliva Sample Ct Values
7	Supplemental Figure 1. Sample collection and inactivation workflow.
8	Supplemental Figure 2. Validation of rLAMP products.
9	Supplemental Figure 3. Cas13 detection on all T7 insertion locations.
10	Supplemental Figure 4. Specificity testing of DISCoVER Assay.
11	Supplemental Figure 5. Temperature characterization of the cartridge using a thermal calibration
12	cartridge.
13	Supplementary Video. Demonstration of the DISCoVER workflow.
14	

15 **Supplementary Table 1: LAMP primer sets screened, Related to Figure 2**

Lamp Primer Set	Time to Amplification (min)	NTC-Amplification time delta (min)	Amplicon length (nt)	Reference
Orflab Set 1	11.6	21.3	9	(Rabe and Cepko 2020)
N Set 2	12.2	28.7	26	(Joung et al., n.d.)
N Set 1	12.5	33.1	46	(Broughton et al. 2020)
Nsp3 Set 1	13.2	30.0	1	(Park et al. 2020)
Orflab Set 2	14.8	25.4	1	(Yu et al. 2020)
N Set 3	14.5	27.1	27	(Zhang et al. 2020)
N Set 4	15.7	25.4	27	(Zhang et al. 2020)

Orflab Set 3	16.7	21.5	0	(Lamb et al., n.d.)
E Set 1	18.0	27.6	60	(Broughton et al. 2020)

16

17 **Supplementary Table 2: LAMP, rLAMP, qRT-PCR, and Cas13 sequences**

18 See attached file

19

20 **Supplementary Table 3: Fluidics calibration volumes**

Volumes (µL)	Saliva	Primer Mix	Master Mix	Cas13+crRNA	T7mix + FQ
Loaded	150	12	40	10	40
Lost	-	8	20	6	8
Reaction	16	4	20	4	32

21

22

23

24

25

26

27 **Supplementary Table 4. Cost breakdown**

Reagents		Prototype (current version)	Point of Care (hypothetical)
Inactivation (per x saliva samples)		\$ 0.23	\$ 0.23
Assay (per cartridge)			
	Primer mix	\$0.42	\$0.42
	Master mix	\$5.51	\$5.51
	Cas13	\$0.17	\$0.17
	T7 mix	\$0.65	\$0.65
	F/Q probe	\$0.06	\$0.06
	crRNA	\$0.005	\$0.005
	Total (1 cartridge)	\$6.82	\$6.82
Instrument			
	Electronic board with temperature controller	\$2000	\$50
	Syringe pump	\$2100	\$100
	Solenoid valves	\$600	\$300

	Manifold components	\$3500	\$200
	Total (1 instrument)	\$8,200	\$650
			Production Volume - 500k
Cartridge	PMMA	\$20	\$2
	Adhesive	\$5	\$0.7
	Hydrophobic membranes	\$2	\$0.5
	Silicone rubber sheet	\$6	\$2
	Labor assembly	\$75	\$3
	Total (1 cartridge)	\$103	\$8
Detection			
	Eyepiece	\$170	\$100
	Camera	\$550	\$10
	Fluorescence filters	\$25	\$40

	Electronic Controllers/boards	\$300	\$30
	LED	\$296	\$15
	Other hardware (mounts, screws, etc)	\$80	\$40
	Total (1 detection system)	\$2583	~\$235*

28 * An optical system designed to deliver similar detection limits but optimized for mass manufacture
29 would have an estimated parts cost (very roughly, cost of goods sold) of less than \$250. In a unit
30 redesigned for production at volume, the camera sensor, high-power LED, and microcontrollers
31 drop to under ~\$10 each even in modest quantities. This leaves filters, optics, mounting and labor
32 as the main cost drivers. Filter size can be reduced to the ~ 4mm diameter of the system aperture,
33 reducing filter cost (on an areal basis) by > 25X to under ~ \$40, and optics (~ \$200) will also drop
34 substantially at volume, approximating the low-cost objective they replace.

35 **Supplementary Table 5. Clinical Saliva Sample Ct Values**

Ct		Donor ID
N	ACTB	
23.20	32.35	4
29.50	32.59	7
31.40	33.15	8
30.64	31.47	17
28.54	32.32	19
29.50	32.39	20
21.86	31.29	32
26.75	33.09	50
23.41	33.02	60
26.42	34.22	64
39.50	32.35	1
41.71	28.56	38
38.69	33.50	49

36

37

38


39

40

41

42

43



44

45 **Supplemental Figure 1. Sample collection and inactivation workflow.** Schematic of
46 inactivation protocol. Clinical saliva could be collectively inactivated at 95C for 5 minutes before
47 being processed individually onto the DISCOVER system.

48

49

50

51

52

53

54

55

56

57


58

59

60

61

62



63

64 **Supplemental Figure 2. Validation of rLAMP products.** A. Schematic of primary mBIP
 65 rLAMP products and sizes upon AfeI digestion (left). Virtual gel depicting expected AfeI
 66 restriction digest bands (147 nt, 128 nt) and resulting transcription bands of mBIP rLAMP
 67 products. Only the 147 nt product is expected to contain the T7 promoter, and thus produce an
 68 ~85nt RNA product upon transcription. B. Restriction-digestion of each rLAMP product with each
 69 primer set containing the different T7 insertion positions.

70

71

72


73

74

75

76

77




78

79 **Supplemental Figure 3. Cas13 detection on all T7 insertion locations**, with T7 transcription
 80 and Cas13 detection occurring in the same reaction. The maximum fluorescence of the synthetic
 81 activator at 10 nM is plotted (dashed line). Values are mean \pm SD with $n = 3$. NTC, no template
 82 control. RNP, ribonucleoprotein.

83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111

112



113

114 **Supplemental Figure 4. Specificity testing of DISCOVER Assay. A.** Detection of SARS-CoV-
115 2 synthetic RNA in inactivated saliva in the presence of H1N2, H3N2, Influenza B, and human
116 coronavirus OC43 synthetic viral RNA with N gene crRNA. Values are mean \pm SD with n = 3. **B.**
117 Detection of synthetic SARS-CoV-2 B.1.1.7. variants in saliva at 50 cp/μL with N gene crRNA.
118 Values are mean \pm SD with n = 3. NTC, no template control.

119

120

121

122

123

124

125

126

127

128

129

130


131

132

133

134

135



136

137 **Supplemental Figure 5. Temperature characterization of the cartridge using a thermal**
 138 **calibration cartridge.** Graph showing the temperature measured via integrated thermal-epoxy
 139 from the rLAMP chamber (A) and the detection chamber (B). On the x-axis, we showed the
 140 different timepoints at which the temperature was changed on the user interface.

141

142

143

144

145

146

147

148
149
150
151
152
153
154
155

Supplementary Video. Demonstration of the DISCOVER workflow. Test samples are collected into saliva collection tubes containing inactivation reagent. The sample is then heat-inactivated at 95°C for 5 minutes and applied to the microfluidic cartridge via transfer pipette. The DISCOVER cartridge comes pre-loaded with reagents necessary for executing the test. Patient information is then inputted into the computer, the cartridge is inserted into the device, and the software is started to begin the test. During the run, data is displayed in real time and automatically resulted.